BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8217818)

  • 1. Evaluation of late cardiotoxicity with pulsed Doppler echocardiography in patients treated for Hodgkin's disease.
    Kreuser ED; Völler H; Behles C; Schröder K; Uhrig A; Besserer A; Thiel E
    Br J Haematol; 1993 Aug; 84(4):615-22. PubMed ID: 8217818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Late cardiac toxicity in Hodgkin's disease. A study with pulsed Doppler echocardiography].
    Völler H; Kreuser ED; Uhrig A; Schröder K; Behles C; Thiel E; Schröder R
    Dtsch Med Wochenschr; 1993 Feb; 118(8):247-53. PubMed ID: 7680306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Echocardiographic evaluation of acute cardiotoxicity in the treatment of Hodgkin disease according to the German Hodgkin's Lymphoma Study Group.
    Krupicka J; Marková J; Pohlreich D; Kozák T; Línková H; Diehl V;
    Leuk Lymphoma; 2002 Dec; 43(12):2325-9. PubMed ID: 12613519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echocardiographic evaluation of early and chronic cardiotoxicity in adult patients treated for Hodgkin's disease with ABVD regimen.
    Elbl L; Vasova I; Kral Z; Navratil M; Smardova L; Vorlicek J
    Neoplasma; 2006; 53(1):62-6. PubMed ID: 16416015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of cardiac function in patients with Hodgkin's disease treated with mediastinal irradiation and combination chemotherapy including doxorubicin.
    LaMonte CS; Yeh SD; Straus DJ
    Cancer Treat Rep; 1986 Apr; 70(4):439-44. PubMed ID: 2421892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens.
    Elbl L; Vasova I; Kral Z; Tomaskova I; Smardova L; Wagnerova B; Jedlicka F; Vorlicek J
    J Chemother; 2006 Apr; 18(2):199-208. PubMed ID: 16736890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The late cardiac sequelae after mantle-field irradiation. The results in Erlangen's patient caseload].
    Friedrich SA; Unverdorben M; Kunkel B; Dunst J
    Strahlenther Onkol; 1996 Jan; 172(1):19-24. PubMed ID: 8571182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
    Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
    Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of a combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin's disease patients with massive initial mediastinal involvement.
    Lagrange JL; Thyss A; Caldani C; Héry M; Schneider M; Bensadoun JR
    Bull Cancer; 1988; 75(8):801-6. PubMed ID: 2460169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease.
    Gustavsson A; Eskilsson J; Landberg T; Svahn-Tapper G; White T; Wollmer P; Akerman M
    Ann Oncol; 1990 Sep; 1(5):355-63. PubMed ID: 2261376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Late complications after treatment of Hodgkin's disease].
    Lund MB; Kongerud J; Boe J; Ihlen H; Forfang K; Abrahamsen AF; Nome O
    Tidsskr Nor Laegeforen; 1999 Mar; 119(7):933-7. PubMed ID: 10210953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females?
    Lund MB; Kongerud J; Boe J; Nome O; Abrahamsen AF; Ihlen H; Forfang K
    Ann Oncol; 1996 Mar; 7(3):257-64. PubMed ID: 8740789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac disease following treatment of Hodgkin's disease in children and adolescents.
    Hancock SL; Donaldson SS; Hoppe RT
    J Clin Oncol; 1993 Jul; 11(7):1208-15. PubMed ID: 8315419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and subclinical cardiac late effects in pediatric Hodgkin's lymphoma survivors.
    Materazzo C; Massimino M; Schiavello E; Podda M; Gandola L; Cefalo G; Catania S; Meazza C; Moschetti I; Terenziani M
    Tumori; 2017 Nov; 103(6):566-571. PubMed ID: 28708228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
    J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease.
    Hancock SL; Tucker MA; Hoppe RT
    JAMA; 1993 Oct; 270(16):1949-55. PubMed ID: 8411552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German-Austrian Study-Group since 1978. German-Austrian Pediatric Hodgkin's Disease Study Group.
    Schellong G
    Ann Oncol; 1996; 7 Suppl 4():67-72. PubMed ID: 8836413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.